Michel Djandji
Overview
Explore the profile of Michel Djandji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
109
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Celli B, Christenson S, Christenson S, Rabe K, Han M, van den Berge M, et al.
Am J Respir Crit Care Med
. 2025 Feb;
PMID: 39938077
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition of the lungs, characterized by chronic respiratory symptoms, primarily dyspnea, cough, and sputum production, due to airway and/or alveoli abnormalities that...
2.
Celli B, Anzueto A, Singh D, Hanania N, Fabbri L, Martinez F, et al.
Chest
. 2024 Dec;
PMID: 39631681
Topic Importance: COPD is a complex, heterogeneous lung disease characterized by persistent airflow limitation secondary to airways and parenchymal abnormalities, and respiratory symptoms, including dyspnea, fatigue, chronic cough, and sputum...
3.
Rabe K, Martinez F, Bhatt S, Kawayama T, Cosio B, Mroz R, et al.
ERJ Open Res
. 2024 Sep;
10(5).
PMID: 39319046
Background: Accumulating data implicate interleukin (IL)-33, a proinflammatory cytokine released locally upon epithelial cell damage, in the pathogenesis of COPD. In a phase 2 study, itepekimab, a human monoclonal antibody...
4.
Papadopoulos N, Szefler S, Bacharier L, Maspero J, Domingo C, Fiocchi A, et al.
Allergy
. 2023 Apr;
78(8):2157-2167.
PMID: 37059696
Background: Cytokines, such as interleukins (IL)-4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for...
5.
Corren J, Jackson D, Casale T, Borish L, Rabe K, Busse W, et al.
J Asthma Allergy
. 2023 Mar;
16:249-260.
PMID: 36915284
Purpose: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In phase 3 QUEST...
6.
Sher L, Corren J, Pavord I, Daizadeh N, Altincatal A, Soler X, et al.
J Asthma
. 2023 Mar;
60(9):1767-1774.
PMID: 36876957
Objective: The open-label extension TRAVERSE study (NCT02134028) assessed dupilumab long-term safety and efficacy in patients who completed Phase 2/3 dupilumab asthma studies. This post hoc analysis evaluated long-term efficacy in...
7.
Brusselle G, Quirce S, Papi A, Kuna P, Chipps B, Hanania N, et al.
J Allergy Clin Immunol Pract
. 2022 Dec;
11(3):873-884.e11.
PMID: 36572184
Background: Type 2 cytokines IL-4/IL-5/IL-13 play an important role in pathogenesis of type 2 conditions, including asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, inhibiting...
8.
Pavord I, Deniz Y, Corren J, Casale T, FitzGerald J, Izuhara K, et al.
J Allergy Clin Immunol Pract
. 2022 Dec;
11(4):1213-1220.e2.
PMID: 36535524
Background: FeNO may have a role as both a prognostic and predictive biomarker in combination with eosinophils for assessing responsiveness to some biological therapies. Objective: We evaluated the value of...
9.
Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Msihid J, Djandji M, et al.
Allergol Int
. 2022 Sep;
72(1):89-99.
PMID: 36114102
Background: Safety and efficacy data for dupilumab beyond 1 year are lacking for patients from Japan with moderate-to-severe asthma. Methods: The TRAVERSE open-label extension (OLE) study (NCT02134028) assessed the safety...
10.
Bourdin A, Virchow J, Papi A, Lugogo N, Bardin P, Antila M, et al.
Respir Med
. 2022 Sep;
202:106938.
PMID: 36087550
Background And Objective: Dupilumab blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), add-on dupilumab...